Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953675 | 0.81 | KDM4E (0.42) | KDM4EHTTKMT2ACYP1A2CYP2C9 | |
| SCHEMBL8936738 | 0.81 | KDM4E (0.42) | KDM4EHTTKMT2ACYP1A2CYP2C9 | |
| SCHEMBL1331644 | 0.80 | L3MBTL1 (0.47) | KMT2ACYP1A2ALDH1A1L3MBTL1LMNA | |
| SCHEMBL10107044 | 0.78 | IDO1 (0.42) | KDM4EHTTKMT2ACYP1A2CYP2C9 | |
| SCHEMBL30994957 | 0.78 | KDM4E (0.39) | KDM4EHTTKMT2ACYP1A2CYP2C9 | |
| SCHEMBL1042131 | 0.78 | KDM4E (0.39) | KDM4EHTTKMT2ACYP1A2CYP2C9 | |
| SCHEMBL31026298 | 0.77 | KDM4E (0.41) | KDM4EHTTKMT2ACYP1A2CYP2C9 | |
| SCHEMBL29276098 | 0.77 | KDM4E (0.38) | KDM4EHTTKMT2ACYP1A2CYP2C9 | |
| SCHEMBL1138862 | 0.77 | L3MBTL1 (0.46) | KDM4EHTTKMT2ACYP1A2CYP2C19 | |
| Water SCHEMBL27635873 | 0.77 | KDM4E (0.38) | KDM4EHTTKMT2ACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100447149-C | COMT inhibitors | HOFFMANN LA ROCHE (CH) | 2008-12-31 | — | — | CN | disclosed |
| US-7319101-B2 | COMT inhibitors for the treatment of depression and impaired cognition | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319101-B2 | COMT inhibitors for the treatment of depression and impaired cognition | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319101-B2 | COMT inhibitors for the treatment of depression and impaired cognition | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1697394-B1 | COMT INHIBITORS | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| CN-1886416-A | COMT inhibitors | HOFFMANN LA ROCHE (CH) | 2006-12-27 | — | — | CN | disclosed |
| EP-1697394-A2 | COMT INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058228-A2 | COMT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058228-A2 | COMT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | COMT, MAOB, TPH1 | KDM4E 1075/4885HTT 447/4885KMT2A 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.